« | Home | Categories | »

Medicare Pricing Delay is Political Win for Amgen, Drug Maker

Posted on January 20th, 2013 at 14:12 by John Sinteur in category: News -- Write a comment


Just two weeks after pleading guilty in a major federal fraud case, Amgen, the world’s largest biotechnology firm, scored a largely unnoticed coup on Capitol Hill: Lawmakers inserted a paragraph into the “fiscal cliff” bill that did not mention the company by name but strongly favored one of its drugs.

The language buried in Section 632 of the law delays a set of Medicare price restraints on a class of drugs that includes Sensipar, a lucrative Amgen pill used by kidney dialysis patients.

The provision gives Amgen an additional two years to sell Sensipar without government controls. The news was so welcome that the company’s chief executive quickly relayed it to investment analysts. But it is projected to cost Medicare up to $500 million over that period.

Amgen, which has a small army of 74 lobbyists in the capital, was the only company to argue aggressively for the delay, according to several Congressional aides of both parties.

previous post: UPDATED: 5 People Shot At 3 Different Gun Shows On Gun Appreciation Day

next post: Dr. Cornel West – Government can be Oppressive